Compare Stocks: BCLI, MGX, IZTC, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$1.00 +1.0%	$1.02	$0.46 ▼ $1.69	$11.27M	0.28	20,827 shs	6,898 shs
GOSS Gossamer Bio	$0.16 -11.2%	$0.17	$0.11 ▼ $3.87	$42.22M	2	19.93 million shs	23.49 million shs
IZTC Invizyne Technologies	$6.31 -7.9%	$6.25	$8.50 ▼ $23.00	$39.45M	N/A	37,647 shs	18,649 shs
MGX Metagenomi	$1.15 -0.9%	$1.22	$1.13 ▼ $3.95	$43.82M	0.67	145,505 shs	147,547 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	-5.71%	-15.20%	+25.70%	+19.35%	+41.35%
GOSS Gossamer Bio	+2.62%	+7.47%	+1.07%	+15.32%	-93.24%
IZTC Invizyne Technologies	0.00%	+1.78%	+34.18%	-12.18%	-42.73%
MGX Metagenomi	-0.85%	-0.85%	-5.69%	-5.69%	-37.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$1.00 +1.0%	$1.02	$0.46 ▼ $1.69	$11.27M	0.28	20,827 shs	6,898 shs
GOSS Gossamer Bio	$0.16 -11.2%	$0.17	$0.11 ▼ $3.87	$42.22M	2	19.93 million shs	23.49 million shs
IZTC Invizyne Technologies	$6.31 -7.9%	$6.25	$8.50 ▼ $23.00	$39.45M	N/A	37,647 shs	18,649 shs
MGX Metagenomi	$1.15 -0.9%	$1.22	$1.13 ▼ $3.95	$43.82M	0.67	145,505 shs	147,547 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	-5.71%	-15.20%	+25.70%	+19.35%	+41.35%
GOSS Gossamer Bio	+2.62%	+7.47%	+1.07%	+15.32%	-93.24%
IZTC Invizyne Technologies	0.00%	+1.78%	+34.18%	-12.18%	-42.73%
MGX Metagenomi	-0.85%	-0.85%	-5.69%	-5.69%	-37.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	0.00	N/A	N/A	N/A
GOSS Gossamer Bio	2.22	Hold	$3.20	1,903.76% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
MGX Metagenomi	2.75	Moderate Buy	$6.00	421.74% Upside

Current Analyst Ratings Breakdown

Latest BCLI, MGX, IZTC, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00 ➝ $5.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
GOSS Gossamer Bio	$48.47M	0.77	N/A	N/A	($0.53) per share	-0.30
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	$25.21M	1.72	N/A	N/A	$4.22 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$1.65	N/A	N/A	N/A	N/A	N/A	-519.50%	11/16/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)

Latest BCLI, MGX, IZTC, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	BCLI Brainstorm Cell Therapeutics	-$0.29	-$0.35	-$0.06	N/A	N/A	N/A
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
GOSS Gossamer Bio	N/A	0.53	0.53
IZTC Invizyne Technologies	N/A	N/A	N/A
MGX Metagenomi	N/A	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
GOSS Gossamer Bio	81.23%
IZTC Invizyne Technologies	N/A
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
GOSS Gossamer Bio	3.74%
IZTC Invizyne Technologies	N/A
MGX Metagenomi	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	11.38 million	8.74 million	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
MGX Metagenomi	236	37.78 million	33.06 million	N/A

BCLI, MGX, IZTC, and GOSS Headlines

Recent News About These Companies

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Metagenomi Therapeutics Inc MGX

August 25, 2026 | morningstar.comM

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

August 25, 2026 | prnewswire.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript

August 20, 2026 | seekingalpha.com

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

August 11, 2026 | theglobeandmail.com

Metagenomi Therapeutics: Q2 Earnings Snapshot

August 10, 2026 | chron.com

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2026 | zacks.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript

July 20, 2026 | seekingalpha.com

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026 | globenewswire.com

Metagenomi Announces Board Changes and Shareholder Meeting Results

June 10, 2026 | tipranks.com

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

June 5, 2026 | prnewswire.com

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50

May 14, 2026 | msn.com

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

May 14, 2026 | finance.yahoo.com

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 11, 2026 | zacks.com

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...

April 16, 2026 | markets.businessinsider.com

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

April 16, 2026 | globenewswire.com

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

April 13, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, MGX, IZTC, and GOSS Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.00 +0.01 (+1.01%)

As of 02:31 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Gossamer Bio NASDAQ:GOSS

$0.16 -0.02 (-11.23%)

Closing price 04:00 PM Eastern

Extended Trading

$0.14 -0.01 (-9.20%)

As of 08:00 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Invizyne Technologies NASDAQ:IZTC

$6.31 -0.54 (-7.88%)

As of 09/8/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Metagenomi NASDAQ:MGX

$1.15 -0.01 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 +0.02 (+1.65%)

As of 07:30 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCLI, MGX, IZTC, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCLI, MGX, IZTC, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCLI, MGX, IZTC, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, MGX, IZTC, and GOSS Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

Gossamer Bio NASDAQ:GOSS

Invizyne Technologies NASDAQ:IZTC

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCLI, MGX, IZTC, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCLI, MGX, IZTC, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCLI, MGX, IZTC, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI, MGX, IZTC, and GOSS Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

Gossamer Bio NASDAQ:GOSS

Invizyne Technologies NASDAQ:IZTC

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools